Discontinuation of metformin therapy
Pro Research Analysisby 
Searched over 200M research papers
Discontinuation of Metformin Therapy: Prevalence and Patterns
Discontinuation of metformin therapy is common among patients with type 2 diabetes, with studies showing that about 15% to 46% of patients stop metformin within the first few years of treatment, depending on the population and follow-up period 1247. Discontinuation rates are highest within the first three months after starting therapy, and many patients experience multiple cycles of stopping and restarting metformin 27. Factors such as age, ethnicity, and healthcare-related variables influence these patterns 24.
Reasons and Predictors for Stopping Metformin
Several factors are associated with a higher likelihood of metformin discontinuation. Older age, a history of chronic kidney disease (CKD), and declining renal function are significant predictors 145. In some cases, discontinuation is prompted by reaching a threshold of reduced kidney function, as per clinical guidelines . Other factors include the presence of comorbidities, use of other diabetes medications, and adverse effects such as gastrointestinal symptoms 410. Regional differences also exist, with discontinuation rates varying across countries and healthcare systems .
Clinical Outcomes After Metformin Discontinuation
Stopping metformin, especially in patients with advanced CKD, is associated with worse clinical outcomes. Studies have found that discontinuation leads to higher risks of major adverse cardiovascular events, heart failure, end-stage kidney disease, and death compared to those who continue metformin, even in patients with low eGFR 68. Glycemic control often worsens after stopping metformin, with increased HbA1c levels and a greater need for alternative therapies, which may carry higher risks of hypoglycemia and weight gain 389. Additionally, the cost of therapy typically increases after switching from metformin to other medications .
Adherence and Reinitiation
Adherence to metformin is generally low, with fewer than half of patients remaining adherent over time 47. Many patients who discontinue metformin eventually restart it, but repeated cycles of discontinuation and reinitiation are common, highlighting the dynamic nature of metformin use . Factors that improve adherence include older age, presence of certain comorbidities, and concurrent use of other chronic medications .
Special Considerations in Chronic Kidney Disease
Recent evidence suggests that continuing metformin in patients with CKD, even with eGFR below 30 ml/min/1.73m², may offer cardiovascular and renal benefits without a significant increase in the risk of lactic acidosis, though this must be balanced against individual patient risk 68. Over time, the likelihood of discontinuing metformin due to reduced renal function has decreased, reflecting evolving clinical guidelines .
Conclusion
Discontinuation of metformin therapy is frequent and influenced by patient characteristics, comorbidities, and healthcare practices. Stopping metformin, particularly in patients with CKD, is linked to worse cardiovascular, renal, and mortality outcomes. Efforts to improve adherence and carefully weigh the risks and benefits of discontinuation, especially in patients with declining renal function, are essential for optimizing diabetes management and patient outcomes 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic